Sep. 3 at 5:02 PM
$XXII is Building Momentum Around its VLN® Reduced-Nicotine Platform.
22nd Century Group says its strategy is focused on expanding retail distribution, increasing SKUs and accelerating sell-through as it targets EBITDA breakeven in 2027.
🔥 Why XXII is worth watching:
• VLN® products feature 95% less nicotine
• FDA-authorized reduced-exposure claims
• Multiple-brand strategy designed to drive cross-selling
• Continued retail expansion
• New blends + reduced-nicotine products in development
• Licensing and partnership opportunities
• Positioned around the potential growth of a new low-nicotine category
XXII is becoming a leader in the emerging reduced-nicotine tobacco market! 📈